Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C21H21ClN2O |
| Molecular Weight | 352.857 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(C)N(C)C(=O)C1=NC(C2=CC=CC=C2Cl)=C3C=CC=CC3=C1
InChI
InChIKey=RAVIZVQZGXBOQO-UHFFFAOYSA-N
InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3
| Molecular Formula | C21H21ClN2O |
| Molecular Weight | 352.857 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
PK-11195 was first discovered by Pharmuka Laboratories. It was found to be antagonist of the Translocator Protein (TSPO) with potential for development in a number of conditions including cancer models, cardiac ischemia, seizures, depression, and anxiety. PK-11195 has been studied extensively in vitro and in animal models. In phase I clinical trials no anti-inchemic effects were found after drug administration. A tritium [3H] labeled and a C-11 labeled version of PK-11195 are both used diagnostically as PET imaging compounds.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6091832 | https://www.ncbi.nlm.nih.gov/pubmed/12558962
Curator's Comment: PK-11195 C-11 is used in PET to visualize brain inflammation in patients with neuronal damage. Activity was shown in mice.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P50637 Gene ID: 12257.0 Gene Symbol: Tspo Target Organism: Mus musculus (Mouse) |
2.4 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
126.9 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
211.4 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
342 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
432.23 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1171.8 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2926.6 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5872.1 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2553568/ |
400 mg single, intravenous dose: 400 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PK-11195 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Improved assays for xenosensor activation based on reverse transfection. | 2015-10 |
|
| Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR). | 2015-03-04 |
|
| TO901317, a potent LXR agonist, is an inverse agonist of CAR. | 2013 |
|
| Synthesis and evaluation of novel carbon-11 labeled oxopurine analogues for positron emission tomography imaging of translocator protein (18 kDa) in peripheral organs. | 2011-09-08 |
|
| Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. | 2011-08-15 |
|
| Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR). | 2011-04-25 |
|
| Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. | 2010-12-05 |
|
| Decreases in binding capacity of the mitochondrial 18 kda translocator protein accompany oxidative stress and pathological signs in rat liver after DMBA exposure. | 2010-10 |
|
| A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells. | 2010-08 |
|
| Human dosimetry of carbon-11 labeled N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide extrapolated from whole-body distribution kinetics and radiometabolism in rats. | 2010-08 |
|
| Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. | 2010-01-25 |
|
| Bacterial ortholog of mammalian translocator protein (TSPO) with virulence regulating activity. | 2009-06-30 |
|
| Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors. | 2006-06-15 |
|
| A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. | 2005-09-15 |
|
| Structure of the Mg-chelatase cofactor GUN4 reveals a novel hand-shaped fold for porphyrin binding. | 2005-05 |
|
| Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. | 2004-11 |
|
| Involvement of steroids in anti-inflammatory effects of peripheral benzodiazepine receptor ligands. | 2004-01-30 |
|
| Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. | 2003-12-01 |
|
| Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. | 2003-07 |
|
| Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria. | 2002-07-01 |
|
| Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. | 2001-04 |
|
| Intrathecally administered flumazenil and PK 11195 precipitate abstinence syndrome in freely moving diazepam dependent rats. | 1996-12-11 |
|
| PK 11195 reduces the brain availability of lindane in rats and the convulsions induced by this neurotoxic agent. | 1995 |
Patents
Sample Use Guides
Mice received an intraperitoneal injection of PK-11195 (30 - 120 mg/kg ) 30 min before inducing convulsions with one of Ro 5-4864, Ro 5-
3663, PTZ or picrotoxin. Results were mixed. PK-11195 significantly reduced the incidence of convulsions caused by Ro 5-4864 but was ineffective at countering seizures brought on by Ro 5-3663 and picrotoxin. Furthermore, PK 11195 had pro-convulsant actions when combined with sub-convulsant doses of strychnine and picrotoxin.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062569
Human breast cancer cell lines MCF-7 and T47D were cultured and viability and proliferation were determined with a CCK-8 assay. A TSPO selective ligand AC-5216 was added to enhance cellular proliferation and production of allopregnanolone. PK-11195 blocked the effects of AC-5216 with IC50 values of 5.4 nM and 6 nM in MCF-7 and T47D cells respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:01:52 GMT 2025
by
admin
on
Mon Mar 31 23:01:52 GMT 2025
|
| Record UNII |
YNF83VN1RL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID7041097
Created by
admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
|
PRIMARY | |||
|
1345
Created by
admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
|
PRIMARY | |||
|
PK-11195
Created by
admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
|
PRIMARY | |||
|
YNF83VN1RL
Created by
admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
|
PRIMARY | |||
|
85532-75-8
Created by
admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
LABELED -> NON-LABELED | |||
|
|
LABELED -> NON-LABELED |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |